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Abstract
Diabetes and cancers are major public health problems in the United 
States and in the world. Epidemiological studies have clearly demonstrated 
the associations and co morbidity between Type 2 Diabetes (T2D) and multiple 
cancers such as endometrial and prostate cancers. However, the mechanism 
of such associations has not been elucidated. Genetic variation is proposed to 
contribute to these diseases, and common genetic variants may explain part 
of the associations among these diseases. Single Nucleotide Polymorphisms 
(SNPs) rs4430796 and rs7501939 within the HNF1B/TCF2 gene (Gene ID: 6928) 
have been observed to be associated with T2D and endometrial and prostate 
cancers in several studies (pleiotropic effects). Future work is needed to assess 
additional genetic loci sharing among these diseases. To better understand the 
genetic etiology of disease comorbidity it will be useful to combine the results of 
Genome-Wide Association Studies (GWAS), gene-gene and gene-environment 
interactions, with the recent rapid advances in Next Generation Sequencing 
(NGS) technologies.
Keywords: Diabetes; Endometrial cancer; Prostate cancer; Genome-wide 
association study; HNF1B/TCF2; Single nucleotide polymorphism; Pleiotropy
HNF1B, also known as Transcription Factor-2 (TCF2), is located 
at 17q12 [16,19,20] and a member of the homeodomain-containing 
super family of transcription factors [20]. Kolatsi-Joannou et al [21] 
detected HNF1B/TCF2 mRNA in liver, pancreas, stomach, and lung 
and suggested that the HNF1B/TCF2 gene may play a role in epithelial 
differentiation. HNF1B is a transcription factor that plays a role in 
kidney and pancreas development [22,23]. Edghill et al [22] found 
early expression of HNF1B/TCF2 in the kidney, liver, bile ducts, 
thymus, genital tract, pancreas, lung, and gut and suggested that the 
HNF1B/TCF2 could act either as a homodimer or as a heterodimer 
with HNF1A. Ma et al [24] concluded that HNF1B regulates renal 
tubulogenesis by controlling expression of suppressor of cytokine 
signaling 3 (SOCS3) (Gene ID: 9021) as an HNF1B target gene in mouse 
kidney. Based on a mouse model, Verdeguer et al [25] hypothesized 
that HNF1B may have function as both a classic transcriptional 
activator and as a bookmarking factor that marks target genes for 
rapid transcriptional reactivation after mitosis. Mutations of HNF1B 
have been described in renal cell carcinoma [26], and epigenetic 
silencing of the gene has been reported in ovarian cancer, as well 
as gastric, pancreatic, and colorectal cell lines [27]. Furthermore, 
HNF1B over-expression has been reported to be a biomarker of clear 
cell carcinoma of the pancreas [28], and of clear cell carcinoma of 
the ovary and its probable precursor ovarian endometriosis [29-32]. 
Moreover, HNF1B encodes a home box transcription factor that 
controls cell proliferation and differentiation in the kidney, pancreas, 
liver, and genital tract tissues [33]. In addition, emerging evidence 
also suggests that HNF1B isform usage may be altered in prostate 
cancer tissue, with up regulated HNF1B isform B expression in 
prostate cancer tissue compared to benign tissue [34].
Susceptibility to diabetes and related diseases
 Previous study has shown that mutation in HNF1B is associated 
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Introduction
 Diabetes and cancers are common chronic diseases and major 
public health problems in the United States (US) and in the world. 
It’s estimated that about 29.1 million people or 9.3% of the population 
have diabetes in the US (National Diabetes Statistics Report, 2014, 
http://www.cdc.gov/diabetes/pubs/statsreport14.htm). Besides, 
about 1.7 million of new cancer cases and 0.6 million of cancer 
deaths are projected to occur in the US in 2014 [1]. Epidemiological 
studies have shown associations between Type 2 Diabetes (T2D) and 
multiple cancers [2-5]. For example, several studies suggest an inverse 
correlation between T2D and prostate cancer [6-10], although some 
studies show inconsistent results [11]. Furthermore, several studies 
suggest possible positive correlations between T2D and certain 
cancers (such as colon, endometrial, stomach, liver, and pancreatic 
cancers) [3-5,9,12]. However, the mechanism of such associations 
is not clear. On the one hand, these correlations may represent 
casual relationships; and on the other hand, they may reflect some 
shared genetic background [13-15]. Recently, several Genome-
Wide Association Studies (GWAS) observed some variants in the 
Hepatocyte nuclear factor-1-beta (HNF1B) gene (Gene ID: 6928) 
associated with endometrial and prostate cancers [9, 16-18] and T2D 
[16] with the effects being in the opposite direction for T2D and 
cancers.
Review Article
Common Genetic Variants in the HNF1B Gene 
Contribute to Diabetes and Multiple Cancers
Ke-Sheng Wang1*, Daniel Owusu1, Yue Pan2 and 
Chun Xu3
1Department of Biostatistics and Epidemiology, East 
Tennessee State University, USA
2Department of Public Health Sciences, University of 
Miami, USA
3Departments of Psychiatry/Neurology, Texas Tech 
University Health Sciences Center, USA
*Corresponding author: Kesheng Wang, Department 
of Biostatistics and Epidemiology, College of Public 
Health, East Tennessee State University, PO Box 70259, 
Lamb Hall, Johnson City, TN 37614-1700, USA, Tel: 1 423 
439 4481; Fax: 1 423 439 4606; Email: wangk@etsu.edu
Received: July 30, 2014; Accepted: August 05, 2014; 




Austin Biomark Diagn 1(1): id1002 (2014)  - Page - 02
Ke-Sheng Wang Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
with maturity-onset diabetes of the young [35]. Later, several studies 
identified some mutants in the HNF1B/TCF2 gene in patients with 
renal cysts and diabetes syndrome [35-40]. Bonny castle et al [2] 
suggested that common variants in HNF1B might play a modest role 
in T2D susceptibility; while Winkler et al [41] identified a common 
Single Nucleotide Polymorphism (SNP) rs757210 in the HNF1B gene 
that was associated with T2D (p=5×10−6). Recently, studies showed 
that two SNPs (rs7501939 and rs4430796) of HNF1B, which were 
previously associated with T2D in Chinese as well as in Caucasians 
using GWAS reported in 2007 [16], showed the association with 
T2D in the Japanese population [42]. More recently, several studies 
in China suggested that the same HNF1B variants (rs7501939 and 
rs4430796) as the study reported in 2007 [16] may be involved in T2D 
risk in Chinese populations [43-45]. Particularly, a GWAS conducted 
among Chinese Hans confirmed rs4430796 associated with T2D 
(p=1.52x10-11) [46]. 
However, available evidence on diabetes and genetic variations 
is inconsistent. For example, polymorphisms in HNF1B did not 
significantly influence insulin or glucose values nor did they predict 
future T2D [47]. Furthermore, no statistical association was observed 
between rs4430796 and 2-h glucose or impaired glucose regulation 
risk, but gene x physical activity interacted to influence impaired 
glucose regulation and 2-h glucose concentrations [33]. In addition, 
rs757210 just had borderline association with higher levels of fasting 
insulin in the Indian population (p=0.05) [48].
Susceptibility to multiple cancers
Rebouissou et al [26] found that HNF1B regulated the expression 
of polycystic kidney and hepatic disease-1 (PKHD1) (Gene ID: 5314) 
and suggested that germ line mutations of the HNF1B may predispose 
to renal tumors, and proposed that HNF1B may function as a tumor 
suppressor gene in chromophobe renal cell carcinogenesis through 
control of PKHD1 expression. By screening aberrantly mentholated 
genes, Terasawa et al [27] suggested that HNF1B/TCF2 is involved in 
the development of ovarian cancers and may represent a useful target 
for their detection and treatment.
Gudmundsson et al [16] performed a GWAS of 1,501 Icelandic 
man with prostate cancer and 11,290 controls, followed by 3 case-
control replication studies in individuals from the Netherlands, 
Spain, and Chicago. They found the associations between prostate 
cancer and the A allele of rs4430796 (OR=1.22, p=1.4 x 10-11 for the 
combined studies) and C allele of rs7501939 (OR=1.19, p = 4.7 x 10-9 
for the combined studies). Using a large GWAS of prostate cancer, 
Thomas et al [18] confirmed the association found by Gudmundsson 
et al [16] with the same SNP rs4430796 (p=9.58 x 10-10). In a large 
2-stage GWAS of prostate cancer, Eeles et al [49] found strong 
associations observed for rs4430796 (random effect model p=10-13) 
and rs7501939 (random effect model p=2 x 10-11). Sun et al [17] carried 
out a fine mapping study of the HNF1B gene and identified a second 
locus (rs11649743) associated with prostate cancer risk. Levin et al 
[50] suggested that rs4430796 and rs7501939 may play a role in early 
onset prostate cancer (before age 50 years). Furthermore, Waters et al 
[51] confirmed the association of rs4430796 with prostate cancer in a 
multiethnic sample of 2,768 incident prostate cancer cases and 2,359 
controls from the Multiethnic Cohort (African Americans, European 
Americans, Latinos, Japanese Americans, and Native Hawaiians). 
Moreover, Berndt et al [52] performed fine-mapping of HNF1B in 
10,272 prostate cancer cases and 9,123 controls of European ancestry 
from 10 case-control studies and found several SNPs (rs4430796, 
rs7405696, rs11649743, and rs4794758) influence prostate cancer. 
This study demonstrates a complex relationship between variants in 
the HNF1B region and prostate cancer risk. Recently, additional study 
suggested that rs757210 was associated with prostate cancer [53].
Spurdle et al [9] identified an endometrial cancer susceptibility 
locus rs4430796 (p = 7.1 × 10-10) that is also associated with risk 
of prostate cancer. Furthermore, Setiawan et al [54] found that 
rs4430796 and rs7501939 were associated with endometrial cancer 
risk in two large case-control studies nested in prospective cohorts: 
the Multiethnic Cohort Study (MEC) and the Women’s Health 
Initiative (WHI). Di Vivo et al [55] replicated previously identified 
associations of endometrial cancer with genetic markers near the 
HNF1B locus. Recently, several studies found that HNF1B (rs4430796) 
is associated with lung cancer in Chinese population [56], prostate 
cancer in African American men [57], Chinese men [58], and Korean 
population [59]. 
Genetic links between diabetes and multiple cancers
Meta-analyses have shown that men with T2D have a reduction in 
their risk of prostate cancer [6,10,60], but the basis for this association 
is unclear. Other studies further supported an inverse association 
between T2D and prostate cancer [61,62]. Recently, Bansal et al [10] 
demonstrated strongest evidence supporting that T2D is significantly 
inversely associated with risk of developing prostate cancer by 
analyzing 8.1 million participants and 132,231 prostate cancer cases 
from 29 cohort and 16 case-control studies. It has been hypothesized 
that this inverse association is due to metabolic and hormonal changes 
associated with T2D as decreased testosterone or insulin, which lead 
to a less carcinogenic environment [6,60]. Alternative explanations 
for such association include unmeasured confounding, decreased 
Prostate-Specific Antigen (PSA) levels in diabetics, effects of T2D 
treatment on prostate cancer risk, and/or shared genetic factors for 
T2D and prostate cancer [51,63,64]. Genetic variation is proposed 
to contribute to both diseases, and common genetic variation may 
explain part of the association between T2D and prostate cancer 
[13,62]. Recently, GWAS provided support for a shared genetic 
contribution to the risk of T2D and prostate cancer. For example, 
in the study by Gudmundsson et al [16], the A allele of rs4430796 
and C allele of rs7501939 variants in HNF1B/TCF2 showed positive 
associations of risk with prostate cancer (OR>1.0), confers protection 
against T2D (OR<1.0). Further study confirmed the association of 
rs4430796 with T2D and prostate cancer and suggested that T2D has 
a protective effect on prostate cancer risk [62]. Stevens et al [65] found 
that 3 SNPs (rs11649743, rs4430796, and rs7501939) were associated 
with prostate cancer and were also associated, with marginal statistical 
significance, with T2D. Recently, Michaela et al [53] found that T 
allele of rs757210 in HNF1B gene is associated with T2D (OR=0.85) 
and risk of prostate cancer. In addition, a more recent study identified 
17 pleiotropic gene loci between prostate cancer and low-density 
lipoprotein, and prostate cancer and triglycerides, respectively [66]. 
However, rs4810671 in Sulfates 2 (SULF2) gene (Gene ID: 55959) 
may interact with rs4430796 in HNF1B in influencing prostate cancer 
and T2D [67].
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It has been reported that increased Body Mass Index (BMI) is a 
major risk factor for both T2D and endometrial cancer, and there is 
a positive correlation between T2D and endometrial cancer risk [68-
70]. Recently, a GWAS has implicated that rs4430796 is associated 
with endometrial cancer (p=7.1 × 10-10) that is also associated with 
risk of prostate cancer and is inversely associated with risk of T2D. 
However, the opposite direction of the effects of rs4430796 on 
endometrial cancer and T2D risk may indicate that the association 
between rs4430796 and endometrial cancer risk is not mediated 
through BMI or T2D [9]. 
A recent meta-analysis examined the two variants (rs4430796 and 
rs7501939) and found them conclusively to have pleiotropic effects 
on both T2D and prostate cancer; however, the pleiotropy apparently 
does not extend to other cancer types (such as breast, lung, colorectal 
or pancreatic cancers or melanoma) [14]. Analysis of several 
lymphocyte-derived gene expression datasets reveals significant 
associations between rs4430796 genotype and HNF1B expression in 
individuals of European ancestry, but not for individuals of African 
ancestry. These observations suggest that the HNF1B may underlie 
the observed association with endometrial cancer risk, but that 
rs4430796 is unlikely to be the causal SNP driving the association [9]. 
Conclusion and Future Direction
The cause of the epidemiological associations among diabetes and 
multiple cancers is not known. The discovery of common risk alleles 
for prostate cancer and endometrial cancer and T2D may reveal 
part of shared etiology among these diseases. However, diabetes and 
cancers are complex diseases which result from the interplay of many 
genetic and environmental factors and potential interactions. Future 
work is needed to assess additional genetic loci sharing among these 
diseases. Examining the contributions of variants and genes across 
biological pathways that link diseases will be an important part of 
characterizing the overlap in genomic architecture across related 
diseases [71].
 It has been suggested that future research should combine 
genetic susceptibility data with T2D phenotype data to determine to 
what degree the association between T2D genetic risk and prostate 
cancer is mediated by T2D or related phenotypes (such as fasting 
glucose, fasting insulin, or glucose tolerance) [62]. Furthermore, the 
elucidation of correlated pleiotropic effects on diverse phenotypes will 
require very large studies, given the generally subtle effects involved. 
Collaborative efforts between multiple teams, as in the current study, 
may offer a suitable approach to answer such questions [14].
In the future, it will be useful to combine the results of GWAS, 
gene-gene and gene-environment interactions, with the recent rapid 
advances in Next Generation Sequencing (NGS) technologies to 
better understand the genetic etiology of diabetes and multiple cancer 
co morbidity.
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